US 11421036
Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11421036 (Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/577